Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study

Published:2008-12 Issue:12 Volume:3 Page:1439-1445
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kubota Kaoru,Nishiwaki Yutaka,Tamura Tomohide,Nakagawa Kazuhiko,Matsui Kaoru,Watanabe Koshiro,Hida Toyoaki,Kawahara Masaaki,Katakami Nobuyuki,Takeda Koji,Yokoyama Akira,Noda Kazumasa,Fukuoka Masahiro,Saijo Nagahiro

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Global cancer statistics in the year 2000;Parkin;Lancet Oncol,2001

2. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer;Schiller;N Engl J Med,2002

3. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan;Ohe;Ann Oncol,2007

4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

5. Erlotinib in previously treated non-small cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature;Frontiers in Oncology;2022-05-18

2. Review of chemotherapy‐associated paronychia;International Journal of Dermatology;2021-07-09

3. Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913;Investigational New Drugs;2020-08-15

4. Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants;Journal of Thoracic Disease;2020-08

5. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis;PLOS ONE;2020-07-14